Holen Sie sich die Stockscreener-App
124.99
2.40%
-3.08
Handel nachbörslich:
125.08
0.09
+0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$128.07
Offen:
$128.34
24-Stunden-Volumen:
9.80M
Relative Volume:
1.41
Marktkapitalisierung:
$155.09B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
19.36
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
-0.17%
1M Leistung:
+1.53%
6M Leistung:
+14.55%
1J Leistung:
+41.02%
1-Tages-Spanne:
$124.54
$128.70
1-Wochen-Bereich:
$122.50
$128.70
52-Wochen-Spanne:
$88.07
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
124.99 | 158.89B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,043.29 | 939.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.07 | 487.91B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.45 | 411.64B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
124.36 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
94.97 | 235.92B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength (GILD) - Seeking Alpha
South Africa is urged by advocates to issue a compulsory license for Gilead's HIV prevention drug - statnews.com
Gilead’s Top Lawyer Leaving After Big Stock Sale, Settlements - news.bloomberglaw.com
Gilead Sciences (NASDAQ:GILD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $673,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets - Yahoo Finance
Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Is Gilead Sciences Inc. (GIS) stock dividend growth reliableVolume Spike & Daily Market Momentum Tracking - newser.com
Gilead Sciences' GC Will Leave Co. Next Month - Law360
Merck’s Two-Drug HIV Regimen Matches Gilead’s Three-Drug TabletMerck & Co (NYSE:MRK) - Benzinga
Without Explanation, Gilead Sciences Parts Ways With GC It Wooed Aboard in 2022 - Law.com
Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters
Gilead Sciences (GILD) Announces Executive Leadership Change - GuruFocus
Gilead at Jefferies London: Strategic Growth and Innovation - Investing.com India
Gilead Sciences (GILD): Assessing Valuation After Strong Shareholder Returns and Product Pipeline Developments - simplywall.st
Gilead Sciences announces departure of executive vice president and general counsel - Investing.com
Gilead Sciences Announces Executive Vice President Departure - TipRanks
WBI Investments LLC Has $1.66 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead says Deborah Telman to step down as evp at Gilead SciencesSEC filing - MarketScreener
Gilead Sciences announces executive departure in December - StreetInsider
Vanguard Group Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Westover Capital Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead reports Trodelvy breast cancer trial missed primary survival endpoint - PMLiVE
'Gilead wants us to rebuild': Why Galapagos isn't allowed to go extinct after turbulent year - Fierce Biotech
Merck HIV pill matches Gilead’s Biktarvy in trial (MRK:NYSE) - Seeking Alpha
Invenio Wealth Partners LLC Buys Shares of 3,333 Gilead Sciences, Inc. $GILD - MarketBeat
SG Americas Securities LLC Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: A Study in Corporate Contrasts - Ad-hoc-news.de
Why Gilead Sciences Inc. (GIS) stock is a strong analyst pickJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing - MarketScreener
Can Gilead Sciences Inc. stock beat market expectations this quarterWeekly Investment Summary & AI Optimized Trade Strategies - newser.com
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa - European AIDS Treatment Group
Gilead Sciences’ (GILD) chief commercial officer sells $3.5m in stock - Investing.com UK
Raiffeisen Bank International AG Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nomura Asset Management Co. Ltd. Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
First doses of HIV prevention drug lenacapavir delivered to Zambia, Eswatini - Reuters
Gilead Sciences, Inc. $GILD is LSV Asset Management's 9th Largest Position - MarketBeat
Thoroughbred Financial Services LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Citizens Financial Group Inc. RI - MarketBeat
Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa - GuruFocus
Gilead ships first lenacapavir doses to sub-Saharan Africa - StreetInsider
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire
Cetera Investment Advisers Purchases 21,966 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3... - Medical Dialogues
Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market - BioSpace
Is It Too Late to Reassess Gilead After Recent Drug Trial Success? - simplywall.st
Will Gilead Sciences Inc. stock deliver long term returnsJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
135,193 |
| Mercier Johanna | Chief Commercial Officer |
Nov 17 '25 |
Sale |
125.86 |
28,000 |
3,524,173 |
107,193 |
2.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):